ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

IBM (NYSE: IBM) and the Massachusetts Institute of Technology today announced the launch of the MIT-IBM Computing Research ...

We are seeking a creative developer with a strong statistics and machine learning background to join Sloan Kettering Institute’s Single Cell Research Initiative (SCRI). The team’s goal is to develop ...

A novel control algorithm has been developed to resolve critical problems induced from a Proportional-Integral-Derivative (PID) controller by automatizing the technical tuning process. The team ...